Top 10 Manufacturers of Pharmaceutical Intermediate CAS No. 174649-09-3 in 2025

Understanding CAS No. 174649-09-3 – A Key Intermediate in Docetaxel Synthesis

CAS No. 174649-09-3 refers to a protected form of the side chain used in Docetaxel synthesis, typically N-tert-butoxycarbonyl (Boc)-protected isoserine derivatives. This intermediate is designed to facilitate the coupling with the taxane core in the semi-synthetic route of Docetaxel, a widely used chemotherapy medication.

It plays a crucial role in ensuring the correct stereochemistry and high purity required for anti-cancer activity, making it a key intermediate in the production of Docetaxel APIs.

Importance of CAS No. 174649-09-3 in Pharmaceutical Manufacturing

Core Component of the Docetaxel Side Chain

This intermediate provides the chiral (2R,3S)-3-phenylisoserine moiety essential for Docetaxel’s bioactivity.

Enhances Stability and Solubility in Synthesis

The Boc protection stabilizes the amine group, facilitating safe handling and efficient reaction during coupling steps.

Ensures Accurate Stereochemistry

Only the (2R,3S) configuration of the intermediate is used to match the required stereostructure of the final active compound.

Used in High-Containment, GMP Production

As part of the Docetaxel supply chain, it must be produced under strict Good Manufacturing Practices (GMP).

In Demand for Generics and Oncology APIs

With rising generic formulations of Docetaxel worldwide, this intermediate is in strong demand from API manufacturers and CDMOs.

Top 10 Manufacturers of CAS No. 174649-09-3

1. Lonza Group

• Location: Basel, Switzerland

• Overview: Lonza is a top-tier supplier of oncology-related intermediates, including advanced Docetaxel side chains like CAS 174649-09-3.

• Specialty: High-purity, GMP-grade taxane intermediates with full regulatory support.

2. Bachem AG

• Location: Bubendorf, Switzerland

• Overview: Bachem is known for producing chiral and Boc-protected amino acid derivatives used in cytotoxic synthesis.

• Specialty: Stereoselective synthesis and high-quality documentation.

3. Eastfine

• Location: Changzhou City, Jiangsu Province, China

• Overview: Eastfine manufactures CAS 174649-09-3 with precise enantiomeric control and reliable batch consistency for global API producers.

• Specialty: Oncology intermediates with strong export capability and cost-effectiveness.

4. Dipharma Francis S.r.l.

• Location: Milan, Italy

• Overview: Dipharma supplies advanced intermediates for antineoplastic APIs with a focus on taxanes and stereochemically pure compounds.

• Specialty: EU GMP production with comprehensive analytical support.

5. CordenPharma

• Location: Plankstadt, Germany

• Overview: CordenPharma supports the full Docetaxel production route, including protected side chains like CAS 174649-09-3.

• Specialty: Contained manufacturing and high-containment synthesis of cytotoxics.

6. PharmaZell Group

• Location: Raubling, Germany

• Overview: PharmaZell offers protected amino acid intermediates and has experience with taxane semi-synthesis processes.

• Specialty: Sustainable and scalable production of Docetaxel building blocks.

7. Carbogen Amcis

• Location: Bubendorf, Switzerland

• Overview: Carbogen Amcis specializes in the synthesis of cytotoxic intermediates under GMP, including chiral Boc-protected molecules.

• Specialty: Advanced containment and high-potency manufacturing services.

8. Almac Group

• Location: Craigavon, Northern Ireland

• Overview: Almac provides contract synthesis for pharmaceutical intermediates like 174649-09-3 used in oncology applications.

• Specialty: Flexible production capacity and short lead times for late-stage intermediates.

9. Enzymaster Life Sciences

• Location: Düsseldorf, Germany

• Overview: Enzymaster uses biocatalysis to produce chiral intermediates such as CAS 174649-09-3 with excellent enantioselectivity.

• Specialty: Green, enzyme-driven processes with regulatory-compliant quality.

10. Sterling Pharma Solutions

• Location: Newcastle, United Kingdom

• Overview: Sterling specializes in custom synthesis of high-potency intermediates and taxane-related compounds.

• Specialty: Tailored synthesis and full regulatory filing support.

Trends in the Pharmaceutical Intermediates Market

Generic Oncology Growth Driving Demand

The expansion of generic Docetaxel increases global demand for key protected intermediates like 174649-09-3.

Greater Focus on Stereochemistry

Manufacturers are investing in advanced synthesis and chiral resolution technologies to improve the enantiomeric purity of side chains.

Containment Infrastructure is Critical

As Docetaxel intermediates are considered high-potency, companies must meet strict occupational exposure and containment standards.

Integrated CDMO Partnerships

API companies prefer to outsource intermediate production to CDMOs that can handle both R&D and GMP manufacturing under one roof.

Sustainability in Chemical Processes

Green chemistry techniques—like biocatalysis and solvent recovery—are being adopted to reduce the environmental impact of taxane intermediate synthesis.

Conclusion

CAS No. 174649-09-3 is a vital Docetaxel side chain intermediate, ensuring successful API production through precise stereochemical integration and process safety. As oncology APIs remain in high demand, manufacturers like Eastfine, Lonza, Dipharma, and others continue to provide the quality, compliance, and scalability required by the global pharmaceutical industry.

This intermediate’s consistent availability, purity, and GMP-grade quality are essential for meeting the increasing needs of oncology treatment worldwide.